Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Carole Diane Mitnick, Sc.D.

Co-Author

This page shows the publications co-authored by Carole Mitnick and Molly Franke.
Connection Strength

6.328
  1. Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study. Am J Respir Crit Care Med. 2021 01 01; 203(1):111-119.
    View in: PubMed
    Score: 0.913
  2. Time for a change: considering regimen changes in analyses of observational drug-resistant TB treatment cohort data. Int J Tuberc Lung Dis. 2020 11 01; 24(11):1151-1155.
    View in: PubMed
    Score: 0.903
  3. Causal inference in tuberculosis treatment studies: bias considerations and data needs. Int J Tuberc Lung Dis. 2019 08 01; 23(8):960-961.
    View in: PubMed
    Score: 0.827
  4. Counting pyrazinamide in regimens for multidrug-resistant tuberculosis. Ann Am Thorac Soc. 2015 May; 12(5):674-9.
    View in: PubMed
    Score: 0.616
  5. Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment. Clin Infect Dis. 2008 Jun 15; 46(12):1844-51.
    View in: PubMed
    Score: 0.383
  6. All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings. Eur Respir J. 2022 01; 59(1).
    View in: PubMed
    Score: 0.246
  7. Sputum culture conversion definitions and analytic practices for multidrug-resistant TB. Int J Tuberc Lung Dis. 2021 07 01; 25(7):596-598.
    View in: PubMed
    Score: 0.236
  8. Time-Dependent Confounding in Tuberculosis Treatment Outcome Analyses: A Review of a Source of Bias. Am J Respir Crit Care Med. 2020 11 01; 202(9):1311-1314.
    View in: PubMed
    Score: 0.226
  9. Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis. Clin Infect Dis. 2020 07 11; 71(2):415-418.
    View in: PubMed
    Score: 0.221
  10. Value of observational data for multidrug-resistant tuberculosis. Lancet Infect Dis. 2019 09; 19(9):930-931.
    View in: PubMed
    Score: 0.208
  11. Fluoroquinolone Resistance Mutation Detection Is Equivalent to Culture-Based Drug Sensitivity Testing for Predicting Multidrug-Resistant Tuberculosis Treatment Outcome: A Retrospective Cohort Study. Clin Infect Dis. 2017 Oct 15; 65(8):1364-1370.
    View in: PubMed
    Score: 0.183
  12. Time to culture conversion and regimen composition in multidrug-resistant tuberculosis treatment. PLoS One. 2014; 9(9):e108035.
    View in: PubMed
    Score: 0.148
  13. Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortality. PLoS One. 2013; 8(3):e58664.
    View in: PubMed
    Score: 0.133
  14. Tuberculosis in children exposed at home to multidrug-resistant tuberculosis. Pediatr Infect Dis J. 2013 Feb; 32(2):115-9.
    View in: PubMed
    Score: 0.132
  15. Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence. Clin Infect Dis. 2013 Mar; 56(6):770-6.
    View in: PubMed
    Score: 0.130
  16. Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet. 2011 Jan 08; 377(9760):147-52.
    View in: PubMed
    Score: 0.114
  17. Recurrence after treatment for pulmonary multidrug-resistant tuberculosis. Clin Infect Dis. 2010 Sep 15; 51(6):709-11.
    View in: PubMed
    Score: 0.112
  18. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med. 2008 Aug 07; 359(6):563-74.
    View in: PubMed
    Score: 0.097
  19. Safety and effectiveness outcomes from a 14-country cohort of patients with multi-drug resistant tuberculosis treated concomitantly with bedaquiline, delamanid and other second-line drugs. Clin Infect Dis. 2022 Mar 04.
    View in: PubMed
    Score: 0.062
  20. Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies Among Market and City Bus Depot Workers in Lima, Peru. Clin Infect Dis. 2022 01 29; 74(2):343-346.
    View in: PubMed
    Score: 0.061
  21. Safety of treatment regimens containing bedaquiline and delamanid in the endTB cohort. Clin Infect Dis. 2022 Jan 13.
    View in: PubMed
    Score: 0.061
  22. Introducing new and repurposed TB drugs: the endTB experience. Int J Tuberc Lung Dis. 2020 10 01; 24(10):1081-1086.
    View in: PubMed
    Score: 0.056
  23. High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients. J Hepatol. 2020 05; 72(5):1028-1029.
    View in: PubMed
    Score: 0.054
  24. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens. BMC Infect Dis. 2019 Aug 20; 19(1):733.
    View in: PubMed
    Score: 0.052
  25. Presumptive treatment of multidrug-resistant tuberculosis in household contacts. Int J Tuberc Lung Dis. 2016 Mar; 20(3):370-5.
    View in: PubMed
    Score: 0.041
  26. Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone Resistance in Mycobacterium tuberculosis. J Clin Microbiol. 2016 Mar; 54(3):727-33.
    View in: PubMed
    Score: 0.040
  27. Concordance of Mycobacterium tuberculosis fluoroquinolone resistance testing: implications for treatment. Int J Tuberc Lung Dis. 2015 Mar; 19(3):339-41.
    View in: PubMed
    Score: 0.038
  28. Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death. Clin Infect Dis. 2014 Jul 01; 59(1):9-15.
    View in: PubMed
    Score: 0.036
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.